ABCL
Abcellera Biologics Inc
NASDAQ: ABCL · HEALTHCARE · BIOTECHNOLOGY
$4.15
+8.64% today
Updated 2026-04-30
Market cap
$1.16B
P/E ratio
—
P/S ratio
15.41x
EPS (TTM)
$-0.49
Dividend yield
—
52W range
$2 – $7
Volume
4.1M
Abcellera Biologics Inc (ABCL) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | $21.49M | $23.49M | $1.01B | $1.32B | $1.54B | $1.49B | $1.36B |
| Cash & equivalents | $10.44M | $7.55M | $594.12M | $476.14M | $386.54M | $133.32M | $156.32M |
| Current assets | $15.16M | $12.64M | $813.33M | $929.80M | $1.03B | $871.99M | $751.37M |
| Total liabilities | $9.88M | $13.24M | $175.03M | $292.84M | $307.63M | $335.78M | $304.47M |
| Current liabilities | $6.43M | $7.89M | $103.49M | $120.68M | $118.32M | $119.01M | $76.61M |
| Long-term debt | $911224.00 | $1.36M | $2.20M | — | — | — | — |
| Shareholder equity | $11.61M | $10.25M | $830.51M | $1.03B | $1.23B | $1.15B | $1.06B |
| Retained earnings | $-2.50M | $-4.72M | $114.20M | $267.67M | $426.19M | $279.79M | $116.93M |
| Accounts receivable | $1.40M | $2.12M | $213.73M | $160.58M | $38.59M | $64.38M | $92.13M |
| Inventory | $1.00 | $163000.00 | $1.41M | $1.67M | $1.53M | $1.11M | — |
| Goodwill | — | — | $31.50M | $47.81M | $47.81M | $47.81M | $47.81M |